This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
ASCO® Genitourinary Cancers Symposium 2023
Presentations
Disitamab Vedotin | Urothelial Carcinoma | Abstract #TPS594
Phase 2 clinical study evaluating the efficacy and safety of disitamab vedotin with or without pembrolizumab in patients with HER2-expressing urothelial carcinoma (RC48G001, trial in progress)